H. Mizutani

机构：Saitama Cancer Center

发表论文 3 篇 · 总被引 14 次 · h-index 2

代表论文

• OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 (2023 · Journal of Thoracic Oncology · 被引 12)
• OA01.04 First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update (2023 · Journal of Thoracic Oncology · 被引 2)
• MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227 (2024 · Annals of Oncology)